Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at BTIG Virtual Biotechnology Conference Transcript

Aug 11, 2020 / 06:30PM GMT
Release Date Price: $28.14 (-1.37%)
Thomas Eugene Shrader
BTIG, LLC, Research Division - MD & Healthcare Analyst

Great. Thank you, Sara. So, exciting time.

Questions & Answers

Thomas Eugene Shrader
BTIG, LLC, Research Division - MD & Healthcare Analyst

Wanted to know a little bit about your thoughts on uptake. How complex is the actual TIL delivery process? Do you have a sense of which hospitals can handle this? Are they the same CAR-T hospitals? Do you have the same sort of expected side effects? Just your thoughts around the original uptake, who's going to be comfortable in the early stages?

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Sure. So we are partnering now with the leading U.S. cancer centers to prepare for the launch of lifileucel. We are targeting about 40 clinical sites at launch. A lot of these sites have had experience directly with TIL as part of our clinical studies.

And as you mentioned, because CAR-T is also a more complex process that has certainly done a good job

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot